In a microsimulation modelling analysis of a population in Ontario, Canada, Kevin ten Haaf and colleagues compare 576 different lung cancer screening policies with different screening frequencies and eligibility criteria.
The National Lung Screening Trial (NLST) showed that screening with low-dose computed tomography (CT) can reduce lung cancer mortality . Although the sensitivity of CT screening in the NLST was reported to be over 90% across the three screening rounds, the reported specificity ranged from 73.4% in the first round to 83.9% in the third round . Overall, 23.3% of the CT screens in the NLST were false positive, which often required additional follow-up CT examinations and, infrequently, invasive procedures (such as a biopsy, bronchoscopy, or thoracotomy) to determine the malignancy of one or more suspicious pulmonary nodules detected by CT screening . Lung cancer screening with three annual screens, as performed in the NLST, was reported to be cost-effective by US standards, yielding estimated cost-effectiveness ratios of US$52,000 per life-year gained and US$81,000 per quality-adjusted life-year gained [2,3]. However, although the cost-effectiveness of lung cancer screening in a population-based setting has been examined previously, it has not been examined extensively [4–9].
To determine the cost-effectiveness of implementing cancer screening programs, microsimulation modeling is invaluable [10,11]. The United States Preventive Services Task Force (USPSTF) recommended lung cancer screening for current and former smokers who have quit within the past 15 y, aged 55 through 80 who smoked at least 30 pack-years . This recommendation was in part based on a comparative modeling study using microsimulation models, as modeling allows one to extrapolate the results of randomized clinical trials and provide information on the long-term benefits and harms for screening programs with different designs and populations than those considered in clinical trials . However, although the modeling study that informed the USPSTF provides an understanding of the trade-offs between the benefits and harms of different screening scenarios, it did not formally consider their cost-effectiveness .
In Ontario, Canada, lung cancer is responsible for the largest proportion of cancer deaths (49.9 per 100,000 individuals) in the population of 13.8 million individuals, despite falling smoking rates [15,28,55,56]. The implementation of a lung cancer screening program, in addition to continued efforts in primary prevention of smoking, could reduce lung cancer mortality. However, concerns have been raised about whether and how such a program can be implemented in a cost-effective manner [14,16]. Previous studies on the cost-effectiveness of population-based lung cancer screening have yielded inconclusive results, ranging from US$18,452–US$66,480 per life-year gained and US$27,756–US$243,077 per quality-adjusted life-year gained [4–9]. However, many of these studies reported the average cost-effectiveness ratios (ACER, the ratio of differences in costs to differences in health effects compared to no screening) of the investigated screening scenarios as the incremental cost-effectiveness ratios (ICER, the ratio of incremental costs to incremental health effects of a screening policy relative to its next best alternative), which can give misleading cost-effectiveness estimates .
Furthermore, these studies considered limited numbers of screening scenarios, providing little information on the effects of screening eligibility criteria, and may have had insufficient numbers of comparator scenarios to yield correct ICERs . The aim of this study was to investigate the benefits (such as lung cancer mortality reduction and the number of life-years gained), harms (such as the number of false-positive results and occurrence of overdiagnosis), and cost-effectiveness of many different lung cancer screening scenarios for the population of Ontario, overcoming some of the limitations of previous studies.
Materials and Methods
This study was approved by the Research Ethics Board of Sunnybrook Health Sciences Centre on behalf of the Institute for Clinical Evaluative Sciences (ICES). Individual consent for access to de-identified data was not required.
The MIcrosimulation SCreening ANalysis (MISCAN) Lung model was used for this analysis. Other versions of the MISCAN model have been used to investigate the cost-effectiveness of screening programs for breast, colorectal, cervical, and prostate cancers [19–22]. The MISCAN-Lung model used in these analyses was previously calibrated to individual-level data from the NLST and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, from which information on the preclinical duration of lung cancer and the effectiveness of CT screening were derived [23,24]. MISCAN-Lung was one of the models used to inform the USPSTF on their recommendations for lung cancer screening . The structure of the model and its underlying assumptions have been described previously and are detailed in S1 Text; the characteristics of the investigated population are described in the following section and in S2 and S3 Texts [23,24].
In brief, MISCAN-Lung simulates life histories for each individual in the considered population from birth until death in the presence and absence of screening. For each individual, a smoking history is generated based on data on the investigated population. A person’s smoking history influences the probability of developing preclinical lung cancer as well as the probability of dying from other causes. The model considers four histological types of lung cancer: adenocarcinoma/large cell carcinoma/bronchioloalveolar carcinoma, squamous cell carcinoma, other non-small cell carcinoma, and small cell carcinoma. Once preclinical lung cancer has developed, it is assumed to progress through stages IA to IV. During each stage, the cancer may be detected due to symptoms, after which the person is assumed to undergo treatment with associated treatment costs. Lung cancer survival after clinical diagnosis is dependent on the histology and stage of the cancer and the person’s gender. If the screening component is activated, preclinical lung cancers may be detected by screening (at the expense of screening-related costs), which may alter a person’s life history: detection by screening allows treatment at an earlier stage, which may cure the individual, allowing him or her to resume a normal (lung cancer-free) life history. The probability that an individual is cured due to early detection differs by the stage at detection. Screening may also result in serious harms, such as overdiagnosis (the detection of a disease that would never have been detected if screening had not occurred), which may lead to unnecessary (invasive) follow-up procedures, treatments, and anxiety. The effects of screening are derived through utilizing information on the preclinical duration of lung cancer, the screen-detectability of lung cancer, and relevant information on the examined population (such as smoking behavior and other-cause mortality corrected for smoking history) to model the life histories of individuals in the presence and absence of screening . Through comparing the life histories in the presence of screening with the corresponding life histories in the absence of screening, MISCAN-Lung can estimate the effectiveness and costs of screening scenarios.
Three different birth cohorts were investigated: 1940–1949 (ages 66–75 in 2015), 1950–1959 (ages 56–65 in 2015), and 1960–1969 (ages 46–55 in 2015). These cohorts represent approximately 5.2 million individuals in 2016 in the age range for which the USPSTF currently recommends lung cancer screening [12,26]. Birth tables for each cohort were derived from information from Statistics Canada and the Ontario Ministry of Finance [26,27]. Ontario-specific data on smoking behavior were used to model smoking initiation and cessation probabilities and the average number of cigarettes smoked per day (divided into five categories) by age and gender for each cohort [28–32]. Life tables by birth year and gender were extracted from the Canadian Human Mortality Database and adjusted for smoking behavior and lung cancer mortality, as shown graphically for persons born in 1955 in S2 Text Figs C–F . Further information on the methods used to model smoking behavior and adjustment of the life tables for smoking behavior is provided in S2 Text. The age- and gender-specific lung cancer incidence, histology proportions, and stage proportions estimated by MISCAN-Lung were compared to observed data from the Ontario Cancer Registry from 2007–2009, in which screening did not occur, and are detailed in S3 Text .
In total, 576 potential screening scenarios were evaluated. The evaluated scenarios considered different combinations of the following characteristics: age to start screening; age to stop screening; screening interval; and screening eligibility regarding cumulative smoking exposure, years since smoking cessation (for former smokers, defined as individuals who have quit smoking permanently), and whether or not former smokers were excluded from further screening after they reach a maximum number of years since cessation (Table 1). Two types of cumulative smoking criteria, of which one is used at a time in an evaluated scenario, were distinguished: the first type was based on the cumulative number of pack-years, used in the NLST (“NLST-like”) ; the second type of cumulative smoking criteria was based on the criteria used in the Dutch-Belgian lung cancer screening trial (NELSON), which evaluated a person’s smoking duration and average number of cigarettes per day separately (“NELSON-like”) . Of the 576 screening scenarios, 216 screening scenarios considered “NLST-like” criteria (including the criteria currently recommended by the USPSTF), whereas 360 screening scenarios considered “NELSON-like” criteria. Perfect attendance to screening was assumed for the base-case investigation. Estimations regarding screen-related procedures such as false-positive results (defined as receiving a positive screening test result when lung cancer is not found after diagnostic work-up), follow-up CT examinations, screen-related biopsies/bronchoscopies, and non-lung cancer-related surgeries were derived from individual-level data from the CT-arm of the NLST and are described in S4 Text. Limited information on morbidity and mortality has been reported from randomized controlled trials. In a subgroup analysis of NELSON participants, 1% of participants were found to have incidental findings that required additional work-up procedures or treatment . However, no information on morbidity or mortality was reported. In the NLST, 0.06% of the positive screening tests in the low-dose CT group that did not result in a diagnosis of lung cancer were associated with a major complication after an invasive procedure . Overall, six individuals with a positive screening test in the low-dose CT group that did not result in a diagnosis of lung cancer died within 60 d after an invasive diagnostic procedure (0.04%), but it was unknown whether these deaths were caused by complications of the diagnostic procedures . Thus, given the low occurrence of invasive procedures along with a low frequency of major complications, the occurrence of morbidity or death related to screen-related follow-up procedures is expected to be minor.
The analyses were conducted from a third-party health care payer perspective. Fully allocated costs for lung cancer treatment were estimated by stage, age, and gender from the date of diagnosis until the date of death or last known date of follow-up (by person-month) through data from the Ontario Health Insurance Plan (OHIP), the Canadian Institute for Health Information (CIHI), the Ontario Drug Benefit Plan database, the Ontario Chronic Care database, the Ontario Home Care database, and the Ontario New Drug Funding Program. These datasets were linked using unique encoded identifiers and were analyzed at the ICES. Controls without a lung cancer diagnosis from the Registered Persons Database (a roster of all OHIP beneficiaries) were matched to 12,713 staged cases of lung cancer from the Ontario Cancer Registry (10 controls matched per case), based on age, sex, median household income, and census tract on the date of diagnosis of the case. Fully allocated costs were estimated similarly for controls. The fully allocated costs of controls were subtracted from the fully allocated costs for cases in order to obtain the attributable costs of lung cancer care by phase of care (initial, continuing, and terminal care) . By incorporating the fully allocated costs of lung cancer care by phase of care, it is taken into account that individuals whose lung cancer death is averted will on average incur higher costs over their remaining lifetime. In MISCAN-Lung, the attributable costs for stage I were assumed for the modeled stages IA and IB, whereas the attributable costs of stage III were assumed for the modeled stages IIIA and IIIB.
Each person’s eligibility for lung cancer screening was assumed to be free of misclassification error. Therefore, upon entering the eligible age range for the considered screening scenarios, each ever-smoking individual was assumed to receive an invitation for a lung cancer risk assessment. It was assumed that half of all ever-smokers would accept this invitation; half of the individuals who participated in the risk assessment were assumed to request a consultation with a primary care physician about their risk. Costs for screening-related events were determined using 2013 data from OHIP and CIHI. The costs for screening invitations and fixed costs related to the screening program, such as costs for the screening registry, program infrastructure, communications, and advertising, were derived from those incurred in the recent establishment of the colorectal screening program administered by Cancer Care Ontario. The costs for risk assessments were estimated assuming that screening program staff trained in health communication would administer the assessments. Fixed costs were counted up to the year in which the last individuals in the cohorts are eligible for screening (2045 for screening scenarios that end at age 75, 2050 for screening scenarios that end at age 80).
All costs were expressed in Canadian dollars (using May 2013 levels as a base) and were adjusted to reflect the May 2015 prices for health care services using the Ontario Consumer Price Index derived from Statistics Canada . A lifetime time horizon for the costs and effects of screening was applied to each simulated person. Annual discount rates of 3% were applied to both costs and effects, using 2015 as the reference year . The estimated attributable costs of lung cancer care by phase of care and the estimated costs related to the screening program are presented in Tables 2 and 3, respectively. To reflect the uncertainty in these cost estimates, sensitivity analyses were performed, which varied the costs by 50%, as described in a later section of this manuscript. Although cost-effectiveness thresholds have been proposed in the past, there is no official cost-effectiveness threshold employed in the Canadian health care system . Therefore, a cost-effectiveness threshold of $50,000 Canadian dollars ($41,114 in May 1, 2015, US dollars) per life-year gained was chosen, similar to previous Canadian cost-effectiveness studies [39,40].
Benefits, Harms, and Cost-Effectiveness of Screening Scenarios
For each screening scenario, the number of lung cancer deaths prevented, life-years gained, proportion of individuals ever screened, number of CT examinations, screen-related biopsies/bronchoscopies, false-positive screens, non-lung cancer-related surgeries, overdiagnoses, and costs were compared with a situation in which screening does not occur, from 2015 onward. Screening scenarios that were more costly and less effective (i.e., fewer life-years gained) than other scenarios were ruled out as non-efficient by simple dominance. Scenarios that were more costly and less effective than a combination of other scenarios were also ruled out as non-efficient by extended dominance. The remaining screening scenarios constitute the frontier of efficient screening scenarios, i.e., the efficient frontier. For each efficient screening scenario, the ICER was determined, calculated as the incremental net costs per incremental life-year gained compared to the previous efficient screening scenario.
A number of sensitivity analyses were performed to investigate which groups of cost estimates and attendance assumptions have the greatest influence on the cost-effectiveness estimates by varying the costs for CT examinations by 50% compared with the base-case analyses, varying the attributable costs of lung cancer care by phase of care by 50% compared with the base-case analyses, and imperfect attendance rates for screening: low attendance (33% overall compliance rate), average attendance (55% overall compliance rate), and high attendance (64% overall compliance rate). Sensitivity analyses were performed for all 576 scenarios to investigate the effects of variations in assumptions on the composition of the efficient frontier.
Screening Scenarios on the Efficient Frontier
The net discounted costs and life-years gained (from 2015 onwards) for each scenario were used to determine the screening scenarios on the efficient frontier, i.e., the scenarios that provide the highest number of life-years gained for their costs, in the base-case analysis, as shown in Figs 1 and 2. The scenarios that are on the efficient frontier are described in Table 4 and shown in Fig 2. A complete overview of the net discounted costs and life-years gained of all investigated screening scenarios is presented in S1 Appendix Figs A–H. All outcomes were reported per 100,000 individuals alive in 2015.
All scenarios on the efficient frontier consist of annual screening (Table 4), while biennial screening is dominated. Assuming a cost-effectiveness threshold of $50,000 Canadian dollars ($41,114 May 1, 2015, US dollars) per life-year gained as acceptable for the Canadian health care system, Scenario #2 was considered optimal: current and former smokers (who quit ≤ 10 y ago) who smoked ≥40 pack-years would be screened annually between ages 55–75, yielding an ICER of $41,136 Canadian dollars ($33,825 May 1, 2015, US dollars) per life-year gained. If 50% lower or higher attributable costs were assumed, the ICER of this scenario was estimated to be $38,240 ($31,444 May 1, 2015, US dollars) or $48,525 ($39,901 May 1, 2015, US dollars), respectively. If 50% lower or higher costs for CT examinations were assumed, the ICER of this scenario was estimated to be $28,630 ($23,542 May 1, 2015, US dollars) or $73,507 ($60,443 May 1, 2015, US dollars), respectively.
In addition, the benefits and harms of all scenarios on the efficient frontier were examined (Table 5). Scenario #2 would reduce lung cancer mortality in the overall population (which includes non-eligible individuals) by 9.05%, preventing 251 lung cancer deaths and gaining 2,531 life-years (undiscounted) over the lifetime of the program (i.e., on average, 10.08 life-years would be gained for each lung cancer death prevented). However, in Scenario #2, 9.56% of the overall population would receive at least one screen, requiring 91,692 CT screens and follow-up examinations. This scenario would lead to 14,729 false-positive screens and 163 surgeries for potentially benign disease (in persons in whom lung cancer is not detected) and 350 biopsies/bronchoscopies (in persons in whom lung cancer is not detected). Ultimately, 12.53% of all screen-detected cancers would be overdiagnosed, leading to 82 overdiagnosed cases. Based on the estimated number of individuals in the examined cohorts in 2016, Scenario #2 is estimated to screen 499,261 individuals at least once, require 4,788,523 CT examinations, and prevent 13,108 lung cancer deaths, while 4,282 cases of lung cancer would be overdiagnosed [26,27]. The average annual non-discounted costs compared to no screening would be approximately $1,400,000 Canadian dollars ($1,151,178 May 1, 2015, US dollars) over the considered time period; however, the annual costs are higher in the first years compared to later years, due to diminishing numbers of individuals meeting the eligibility criteria. For example, the average non-discounted costs compared to no screening are approximately $5,000,000 Canadian dollars ($4,111,350 May 1, 2015, US dollars) for 2015–2020 compared with approximately $1,600,000 Canadian dollars ($1,315,632 May 1, 2015, US dollars) in 2030–2035.
Effects of Screening Scenario Characteristics on Cost-Effectiveness
Scenarios with older starting ages have lower costs compared with scenarios that start at younger ages but also yield a smaller number of life-years gained (S1 Appendix Fig A). Raising the age to stop screening from 75 to 80 increases the costs and the number of life-years gained, but differences are modest (S1 Appendix Fig B). A comparison of scenarios by smoking eligibility criteria indicates that there is little difference between using NLST-like or NELSON-like smoking eligibility criteria (S1 Appendix Fig C).
S1 Appendix Figs D–G demonstrate the importance of cumulative smoking criteria on cost-effectiveness. Each increase in the cumulative smoking requirement for enrollment substantially decreases the costs while modestly decreasing the number of life-years gained in both NLST-like (S1 Appendix Fig D) and NELSON-like (S1 Appendix Fig E) screening scenarios. In other words, scenarios that apply stringent cumulative smoking eligibility criteria are closer to the efficient frontier than those that apply less restrictive cumulative smoking eligibility criteria. In general, scenarios that require only 20 pack-years are dominated by scenarios that apply more stringent (higher) pack-year criteria.
Increasing the maximum number of years since smoking cessation (S1 Appendix Fig F) and not excluding individuals from further screening once they reach the maximum number of years since cessation (S1 Appendix Fig G) both increase the costs and the numbers of life-years gained. However, the effects of these criteria are less pronounced than those related to cumulative smoking requirements.
S1 Appendix Fig H shows the effects of annual screening compared with biennial screening. Although biennial screening scenarios have substantially lower costs compared with annual screening scenarios, the life-years gained are also substantially lower. S1 Appendix Fig H demonstrates that annual screening scenarios dominate biennial screening scenarios.
Altering assumptions about attendance rates, CT examination costs, and attributable costs impacted the scenarios on the efficient frontier in the base-case analysis to varying degrees. Fig 3 provides an overview of the scenarios on the efficient frontier in the base-case analysis along with the discounted life-years gained and costs for these scenarios in the sensitivity analyses.
Altering assumptions also impacted the composition of the efficient frontier, as shown in S5 Text. When the attendance rates were varied, lower attendance rates were observed to shift scenarios with less restrictive criteria, especially with regards to smoking behavior, on the efficient frontier (S5 Text Tables A–C). This may be due to the fixed costs of the screening scenarios, which are independent of the number of screened individuals; at lower levels of participation these costs have a greater influence on the cost-effectiveness than the costs of CT examinations.
When the attributable costs were varied, it was observed that halving the attributable costs had little effect on the scenarios on the efficient frontier (S5 Text Table D). When the attributable costs were doubled, it was observed that scenarios with less restrictive criteria, especially with regards to smoking cessation, were shifted on the efficient frontier (S5 Text Table E).
When the costs of CT examinations were varied, it was observed that halving the costs of CT examinations also shifted scenarios with less restrictive criteria, in particular with regards to smoking cessation, on the efficient frontier (S5 Text Table F). Doubling the costs of CT examinations had the greatest effect of all sensitivity analyses; the scenarios with the most restrictive criteria with regards to age and smoking were shifted on the efficient frontier and the least costly scenarios on this efficient frontier favored biennial screening (S5 Text Table G).
Scenario #2 was on the efficient frontier across all sensitivity analyses, with the exception of assuming the lowest attendance rates (S5 Text Table H). In contrast, although Scenario #5 closely resembles the eligibility criteria that were used in the NLST, it was not on the efficient frontier in any of the sensitivity analyses.
This simulation study indicates that lung cancer screening can be cost-effective in a population-based setting when eligibility is restricted to high-risk groups. In contrast, utilizing loose eligibility criteria yields nonoptimal and potentially cost-ineffective scenarios, as the cost-effectiveness of lung cancer screening is highly dependent on scenario characteristics, primarily the smoking eligibility criteria. Scenarios that utilize stringent smoking eligibility criteria are more cost-effective than scenarios that utilize less restrictive smoking eligibility criteria due to a focus on individuals at higher risk of developing lung cancer. This greatly reduces the number of screening examinations while still screening those at highest risk. Thus, the level of lung cancer risk at which an individual is eligible for lung cancer screening should be considered before implementing lung cancer screening policies. Future research should investigate the cost-effectiveness of lung cancer screening selection based on accurate lung cancer risk prediction models using suitable risk thresholds [41–43].
The results of this study suggest that the greater reduction in lung cancer mortality and number of life-years gained by annual screening outweigh the costs of the additional number of CT examinations compared with biennial screening, which has previously been suggested to be equally or more cost-effective than annual screening [14,44]. However, previous studies indicated that lung cancer may be more difficult to detect in stage IA with biennial screening . As survival in stage IA is considerably higher compared with other stages, the potential for mortality reduction and life-years gained is higher for annual screening compared to biennial screening . This is supported by the modeling study that informed the USPSTF, which showed that annual screening provides substantial benefits over biennial screening at modest diminishing returns .
Previous studies that examined the cost-effectiveness of lung cancer screening only considered limited numbers of screening scenarios, which provided limited information on the effects of scenario characteristics [4–8]. The results of this study suggest that scenario characteristics, especially smoking eligibility criteria and screening interval, influence the cost-effectiveness of a scenario and suggest that a large variety of scenarios should be considered. In addition, considering a wide variety of screening scenarios provides sufficient comparator scenarios to yield appropriate ICERs . Previous studies often reported the ACERs of the investigated screening scenarios as the ICERs, which can give misleading cost-effectiveness estimates . This study provides both the ACERs and the ICERs of the scenarios on the efficient frontier, in contrast to previous studies that generally did not report an efficient frontier [4–8]. The robustness of the scenarios on the efficient frontier in this study is demonstrated by the sensitivity analyses of all 576 scenarios. This study incorporates both allocated costs for all screening-related procedures and attributable costs for various stages of lung cancer care, which were derived from government data in a province with universal health care, which allows for more comprehensive and accurate cost estimates compared with other studies. Furthermore, this study incorporates detailed information on smoking behavior and smoking-related mortality in contrast to previous studies. Finally, although the majority of previous studies only reported the number of life-years gained, this study reports a variety of benefits (such as lung cancer mortality reduction and the number of life-years gained) and harms (such as the number of false-positive results and the occurrence of overdiagnosis).
This study has some limitations; for example, quality of life was not incorporated in the analyses. There may be some differences in quality of life between annual and biennial screening, as more frequent screening will increase the impact of screening and follow-up–related effects on quality of life. However, results from the NELSON trial indicate that although CT lung cancer screening has a minor impact on quality of life in the short term, the long-term effects are negligible [46,47]. In addition, utility estimates for lung cancer care are highly variable .
Another limitation is that assumptions for follow-up procedures were based on data from the NLST, which may not be generalizable to a population-based setting, as screening algorithms with reduced false-positive rates are being investigated [1,49–51]. By reducing the false-positive rates, the number of unnecessary follow-up CTs and invasive diagnostic procedures may be reduced as well, further improving the cost-effectiveness of lung cancer screening.
Finally, although fully allocated costs for lung cancer care and observed costs for the administration of a cancer screening program were incorporated in the analyses, the government of Ontario only reimburses the physician costs of a CT examination. However, capital investments would be required to acquire the CT scanners necessary to implement a lung cancer screening program, which could influence the costs per CT examination. Conversely, the increased CT capacity could potentially lead to discounts on the costs per CT examination.
This study used a cost-effectiveness threshold of $50,000 Canadian dollars ($41,114 May 1, 2015, US dollars) per life-year gained, similar to previous Canadian cost-effectiveness studies . However, the acceptable ratio between costs and effects differs between countries. For example, although a cost-effectiveness threshold of US$100,000 per quality-adjusted life-year has been proposed for the US, the United Kingdom’s National Institute for Health and Care Excellence uses a £20,000–£30,000 ($30,274–$45,411 May 1, 2015, US Dollars) threshold to determine cost-effectiveness [3,52,53]. Thus, the optimal screening scenario depends in part on the chosen cost-effectiveness threshold: if a cost-effectiveness threshold of $60,000 Canadian dollars ($49,336 May 1, 2015, US dollars) per life-year gained was chosen, Scenario #3 (annual screening for persons aged 55–75 who smoked at least 30 pack-years and currently smoke or quit smoking less than 10 y ago) would have been considered the optimal scenario. However, the ICER of Scenario #2 (annual screening for persons aged 55–75 who smoked at least 40 pack-years and currently smoke or quit smoking less than 10 y ago) remained below the proposed cost-effectiveness threshold of $50,000 Canadian dollars per life-year gained in 5 out of 7 sensitivity analyses (71.4%) with a range of $28,630–$73,507 Canadian dollars per life-year gained. This suggests that both the dominance and cost-effectiveness of Scenario #2 are robust across various sensitivity analyses.
Although our results suggest that a uniform biennial screening interval is dominated by a uniform annual screening interval, recent studies suggest it may be possible to identify individuals for whom biennial screening intervals could be recommended. NLST participants with a negative prevalence screen had a substantially lower risk of developing lung cancer compared to individuals with a positive prevalence screen . Results from the NELSON trial suggest that the 2-y probability of developing lung cancer after a CT screen varied substantially by nodule size and volume doubling time . Future research should evaluate whether the interval between screens can be varied based on previous screening results and what impact this has on cost-effectiveness. In addition, precision medicine could improve the treatment of selected individuals, and biomarkers might help to distinguish between indolent nodules and aggressive nodules requiring rapid diagnosis and treatment. The impacts of these future developments need to be assessed.
In conclusion, this study indicates that lung cancer screening can be cost-effective in a population-based setting if stringent smoking eligibility criteria are applied. Annual screening scenarios are more cost-effective than biennial screening scenarios.
1. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. New England Journal of Medicine. 2011;365(5):395–409. PubMed Central PMCID: PMC 21714641 doi: 10.1056/NEJMoa1102873 21714641
2. Black WC, Gareen IF, Soneji SS, Sicks JD, Keeler EB, Aberle DR, et al. Cost-Effectiveness of CT Screening in the National Lung Screening Trial. New England Journal of Medicine. 2014;371(19):1793–802. doi: 10.1056/NEJMoa1312547 25372087
3. Neumann PJ, Cohen JT, Weinstein MC. Updating Cost-Effectiveness—The Curious Resilience of the $50,000-per-QALY Threshold. New England Journal of Medicine. 2014;371(9):796–7. doi: 10.1056/NEJMp1405158 25162885
4. McMahon PM, Kong CY, Bouzan C, Weinstein MC, Cipriano LE, Tramontano AC, et al. Cost-effectiveness of computed tomography screening for lung cancer in the United States. Journal of Thoracic Oncology. 2011;6(11):1841–8. Epub 2011/09/06. PubMed Central PMCID: PMC3202298. doi: 10.1097/JTO.0b013e31822e59b3 21892105
5. Pyenson BS, Sander MS, Jiang Y, Kahn H, Mulshine JL. An Actuarial Analysis Shows That Offering Lung Cancer Screening As An Insurance Benefit Would Save Lives At Relatively Low Cost. Health Affairs. 2012;31(4):770–9. doi: 10.1377/hlthaff.2011.0814 22492894
6. Villanti AC, Jiang Y, Abrams DB, Pyenson BS. A Cost-Utility Analysis of Lung Cancer Screening and the Additional Benefits of Incorporating Smoking Cessation Interventions. PLoS ONE. 2013;8(8):e71379. doi: 10.1371/journal.pone.0071379 23940744
7. Mahadevia PJ, Fleisher LA, Frick KD, Eng J, Goodman SN, Powe NR. Lung cancer screening with helical computed tomography in older adult smokers: A decision and cost-effectiveness analysis. JAMA. 2003;289(3):313–22. 12525232
8. Goffin JR, Flanagan WM, Miller AB, et al. Cost-effectiveness of lung cancer screening in Canada. JAMA Oncology. 2015;1(6):807–13. doi: 10.1001/jamaoncol.2015.2472 26226181
9. Raymakers AJN, Mayo J, Lam S, FitzGerald JM, Whitehurst DGT, Lynd LD. Cost-Effectiveness Analyses of Lung Cancer Screening Strategies Using Low-Dose Computed Tomography: a Systematic Review. Applied Health Economics and Health Policy. 2016:1–10.
10. Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, et al. Effects of Mammography Screening Under Different Screening Schedules: Model Estimates of Potential Benefits and Harms. Annals of Internal Medicine. 2009;151(10):738–47. doi: 10.7326/0003-4819-151-10-200911170-00010 19920274
11. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating Test Strategies for Colorectal Cancer Screening: A Decision Analysis for the U.S. Preventive Services Task Force. Annals of Internal Medicine. 2008;149(9):659–69. 18838717
12. Moyer VA. Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine. 2014;160(5):330–8. doi: 10.7326/M13-2771 24378917
13. de Koning HJ, Meza R, Plevritis SK, ten Haaf K, Munshi VN, Jeon J, et al. Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S. Preventive Services Task Force. Annals of Internal Medicine. 2014;160(5):311–20. doi: 10.7326/M13-2316 24379002
14. Field JK, Oudkerk M, Pedersen JH, Duffy SW. Prospects for population screening and diagnosis of lung cancer. The Lancet. 2013;382(9893):732–41.
15. Corsi D, Boyle M, Lear S, Chow C, Teo K, Subramanian SV. Trends in smoking in Canada from 1950 to 2011: progression of the tobacco epidemic according to socioeconomic status and geography. Cancer Causes Control. 2014;25(1):45–57. doi: 10.1007/s10552-013-0307-9 24158778
16. Sox HC. Better Evidence about Screening for Lung Cancer. New England Journal of Medicine. 2011;365(5):455–7. doi: 10.1056/NEJMe1103776 21714644
17. O’Mahony JF, Normand C. HIQA's CEA of Breast Screening: Pragmatic Policy Recommendations are Welcome, but ACERs Reported as ICERs are Not. Value in Health. 2015;18(8):941–5. doi: 10.1016/j.jval.2015.08.009 26686777
18. O’Mahony JF, Naber SK, Normand C, Sharp L, O’Leary JJ, de Kok IMCM. Beware of Kinked Frontiers: A Systematic Review of the Choice of Comparator Strategies in Cost-Effectiveness Analyses of Human Papillomavirus Testing in Cervical Screening. Value in Health. 2015;18(8):1138–51. doi: 10.1016/j.jval.2015.09.2939 26686801
19. de Gelder R, Bulliard J- L, de Wolf C, Fracheboud J, Draisma G, Schopper D, et al. Cost-effectiveness of opportunistic versus organised mammography screening in Switzerland. European Journal of Cancer. 2009;45(1):127–38. doi: 10.1016/j.ejca.2008.09.015 19038540
20. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Boer R, Wilschut J, Habbema JDF. At what costs will screening with CT colonography be competitive? A cost-effectiveness approach. International Journal of Cancer. 2009;124(5):1161–8. doi: 10.1002/ijc.24025 19048626
21. Heijnsdijk EAM, de Carvalho TM, Auvinen A, Zappa M, Nelen V, Kwiatkowski M, et al. Cost-effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data. Journal of the National Cancer Institute. 2015;107(1).
22. de Kok IM, van Rosmalen J, Dillner J, Arbyn M, Sasieni P, Iftner T, et al. Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ. 2012;344.
23. Meza R, ten Haaf K, Kong CY, Erdogan A, Black WC, Tammemagi MC, et al. Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. Cancer. 2014;120(11):1713–24. doi: 10.1002/cncr.28623 24577803
24. ten Haaf K, van Rosmalen J, de Koning HJ. Lung Cancer Detectability by Test, Histology, Stage, and Gender: Estimates from the NLST and the PLCO Trials. Cancer Epidemiology Biomarkers & Prevention. 2015;24(1):154–61.
25. ten Haaf K, de Koning HJ. Overdiagnosis in lung cancer screening: why modelling is essential. Journal of Epidemiology and Community Health. 2015;69(11):1035–9. doi: 10.1136/jech-2014-204079 26071497
26. Ontario Ministry of Finance, Ontario Population Projections Update, 2011–2036. Spring 2012.
27. Statistics Canada, CANSIM, table 051–0001., http://www5.statcan.gc.ca/cansim/a26?lang=eng&retrLang=eng&id=0510001&&pattern=&stByVal=1&p1=1&p2=1&tabMode=dataTable&csid=, Accessed on 22-01-2016.
28. Statistics Canada 2011. Canadian Community Health Survey (CCHS), Cycle 1.1, 2.1, 3.1, 4.1 and 2008, 2009, 2010 Annual Component surveys [Microdata]. Ottawa Ontario: Statistics Canada Health Statistics Division [producer and distributor]: Ottawa Ontario: Data Liberation Initiative [distributor].
29. Statistics Canada 2012. National Population Health Survey (NPHS), Cycle 1–9: Household Component—Longitudinal [Canada] [Microdata]. Ottawa Ontario: Statistics Canada Health Statistics Division [producer and distributor]: Ottawa Ontario: Data Liberation Initiative [distributor].
30. Statistics Canada. 1986. General Social Survey, Cycle 1, 1985 [Canada]: Health and Social Support [public use microdata file]. Ottawa, Ontario: Statistics Canada [producer and distributor].
31. Statistics Canada. Survey of Smoking Habits, 1971–1986 [Canada] [Public-use microdata file(s)]. Ottawa, Ontario: Special Surveys Division, Statistics Canada [producer and distributor]. Ottawa, Ontario: Data Liberation Initiative [distributor].
32. Canadian Human Mortality Database. Department of Demography, Université de Montréal (Canada). www.demo.umontreal.ca/chmd/ (data downloaded on 14-03-2014). [Internet].
34. van Iersel CA, de Koning HJ, Draisma G, Mali WPTM, Scholten ET, Nackaerts K, et al. Risk-based selection from the general population in a screening trial: Selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). International Journal of Cancer. 2007;120(4):868–74. doi: 10.1002/ijc.22134 17131307
35. van de Wiel JCM, Wang Y, Xu DM, van der Zaag-Loonen HJ, van der Jagt EJ, van Klaveren RJ, et al. Neglectable benefit of searching for incidental findings in the Dutch—Belgian lung cancer screening trial (NELSON) using low-dose multidetector CT. European Radiology. 2007;17(6):1474–82. doi: 10.1007/s00330-006-0532-7 17206426
36. Yabroff KR, Mariotto AB, Feuer E, Brown ML. Projections of the costs associated with colorectal cancer care in the United States, 2000–2020. Health Economics. 2008;17(8):947–59. doi: 10.1002/hec.1307 17910108
37. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Canadian Medical Association Journal. 1992;146(4):473–81. 1306034
38. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. REcommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276(15):1253–8. 8849754
39. Telford JJ, Levy AR, Sambrook JC, Zou D, Enns RA. The cost-effectiveness of screening for colorectal cancer. Canadian Medical Association Journal. 2010;182(12):1307–13. doi: 10.1503/cmaj.090845 20624866
40. http://www.exchange-rates.org/Rate/CAD/USD/5-1-2015, accessed on 01-09-2016.
41. Kovalchik SA, Tammemagi M, Berg CD, Caporaso NE, Riley TL, Korch M, et al. Targeting of Low-Dose CT Screening According to the Risk of Lung-Cancer Death. New England Journal of Medicine. 2013;369(3):245–54. doi: 10.1056/NEJMoa1301851 23863051
42. Raji OY, Duffy SW, Agbaje OF, Baker SG, Christiani DC, Cassidy A, et al. Predictive Accuracy of the Liverpool Lung Project Risk Model for Stratifying Patients for Computed Tomography Screening for Lung CancerA Case–Control and Cohort Validation Study. Annals of Internal Medicine. 2012;157(4):242–50. doi: 10.7326/0003-4819-157-4-201208210-00004 22910935
43. Tammemägi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, et al. Selection Criteria for Lung-Cancer Screening. New England Journal of Medicine. 2013;368(8):728–36. doi: 10.1056/NEJMoa1211776 23425165
44. Duffy SW, Field JK, Allgood PC, Seigneurin A. Translation of research results to simple estimates of the likely effect of a lung cancer screening programme in the United Kingdom. 2014;110(7):1834–40. doi: 10.1038/bjc.2014.63 24525696
45. Groome PA, Bolejack V, Crowley JJ, Kennedy C, Krasnik M, Sobin LH, et al. The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours. Journal of Thoracic Oncology. 2(8):694–705. doi: 10.1097/JTO.0b013e31812d05d5 17762335
46. van den Bergh KAM, Essink-Bot ML, Borsboom GJJM, Scholten ET, van Klaveren RJ, de Koning HJ. Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial. European Respiratory Journal. 2011;38(1):154–61. doi: 10.1183/09031936.00123410 21148229
47. van den Bergh KAM, Essink-Bot ML, Borsboom GJJM, Th Scholten E, Prokop M, de Koning HJ, et al. Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON). British Journal of Cancer. 2009;102(1):27–34. doi: 10.1038/sj.bjc.6605459 19935789
48. Sturza J. A Review and Meta-Analysis of Utility Values for Lung Cancer. Medical Decision Making. 2010;30(6):685–93. doi: 10.1177/0272989X10369004 20448248
49. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of ct screening for lung cancer: A systematic review. JAMA. 2012;307(22):2418–29. doi: 10.1001/jama.2012.5521 22610500
50. Pinsky PF, Gierada DS, Black W, Munden R, Nath H, Aberle D, et al. Performance of Lung-RADS in the National Lung Screening Trial: A Retrospective Assessment. Annals of Internal Medicine. 2015;162(7):485–91. doi: 10.7326/M14-2086 25664444
51. Horeweg N, van Rosmalen J, Heuvelmans MA, van der Aalst CM, Vliegenthart R, Scholten ET, et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. The Lancet Oncology. 2014;15(12):1332–41. doi: 10.1016/S1470-2045(14)70389-4 25282285
52. http://www.exchange-rates.org/Rate/GBP/USD/5-1-2015, accessed on 01-09-2016.
53. National Institute for Health and Care Excellence. Developing NICE Guidelines: The Manual [Internet]. London: National Institute for Health and Care Excellence (NICE); 2015 Jul 22. Process and Methods Guides No. 20. http://www.ncbi.nlm.nih.gov/books/NBK310375/.
54. Patz EF Jr, Greco E, Gatsonis C, Pinsky P, Kramer BS, Aberle DR. Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial. The Lancet Oncology. 2016;17(5):590–9. doi: 10.1016/S1470-2045(15)00621-X 27009070
55. Cancer Care Ontario. Cancer Fact: Lung cancer accounts for largest proportion of premature Ontario cancer deaths. Available from: http://www.cancercare.on.ca/cancerfacts.
56. Cancer Care Ontario. Cancer statistics 2012. Available from: http://www.cancercare.ca/ocs/csurv/stats/ontario/.